Objectives: Type II diabetes mellitus (T2DM) is regarded as a serious illness characterized by high levels of blood sugar due to insulin resistance or insufficient insulin production. T2DM affects millions of people worldwide and is the primary reason for morbidity and mortality. Thus, it is essential to analyze the effect of T2DM on patients. Even though prevailing research has strived to identify the impact of T2DM on several ailments like cardiovascular diseases, neuropathy, retinopathy, and nephropathy. It has disregarded few aspects like pulmonary function, duration of diabetes, and glycemic status. The present study investigates the effect of T2DM on pulmonary function in relation to glycaemia status and duration of diabetes.
Methods: The cross-sectional research is performed on a total of 140 patients with T2DM from the Medical Department. Further, the congregated sample is investigated using SPSS software. The relevant statistical methods are utilized to analyze the research results. The ANOVA analysis reveals the impact of T2DM on pulmonary function; further, the correlation analysis unveils the association among glycemic status, pulmonary function of patients, and duration of diabetes with T2DM.
Results: The outcomes of the research will contribute to revealing the impact of T2DM on pulmonary function in relation to glycemic status and diabetes duration.
Conclusions: The outcomes offer valuable insights into the lung function of patients with T2DM and help in prior treatment for enhancing the pulmonary health. Finally, the proposed research will aid healthcare professionals in better management of T2DM in patients and its related complications.
{"title":"A cross sectional study on effect of glycaemic status and duration of type II diabetes mellitus on the pulmonary function.","authors":"Praveena Meyyazhagan, Thamaraiselvi Kanagaraj, Nachal Annamalai","doi":"10.1515/jbcpp-2024-0190","DOIUrl":"10.1515/jbcpp-2024-0190","url":null,"abstract":"<p><strong>Objectives: </strong>Type II diabetes mellitus (T2DM) is regarded as a serious illness characterized by high levels of blood sugar due to insulin resistance or insufficient insulin production. T2DM affects millions of people worldwide and is the primary reason for morbidity and mortality. Thus, it is essential to analyze the effect of T2DM on patients. Even though prevailing research has strived to identify the impact of T2DM on several ailments like cardiovascular diseases, neuropathy, retinopathy, and nephropathy. It has disregarded few aspects like pulmonary function, duration of diabetes, and glycemic status. The present study investigates the effect of T2DM on pulmonary function in relation to glycaemia status and duration of diabetes.</p><p><strong>Methods: </strong>The cross-sectional research is performed on a total of 140 patients with T2DM from the Medical Department. Further, the congregated sample is investigated using SPSS software. The relevant statistical methods are utilized to analyze the research results. The ANOVA analysis reveals the impact of T2DM on pulmonary function; further, the correlation analysis unveils the association among glycemic status, pulmonary function of patients, and duration of diabetes with T2DM.</p><p><strong>Results: </strong>The outcomes of the research will contribute to revealing the impact of T2DM on pulmonary function in relation to glycemic status and diabetes duration.</p><p><strong>Conclusions: </strong>The outcomes offer valuable insights into the lung function of patients with T2DM and help in prior treatment for enhancing the pulmonary health. Finally, the proposed research will aid healthcare professionals in better management of T2DM in patients and its related complications.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"39-50"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Numerous studies show that the adipokines play a role in on the thyroid axis. The aim of this study was the evaluation of serum level of CTRP-3 and CTRP-6 as a member of the adipokines family in patients with Hashimoto's.
Methods: The levels of CTRP-3 and CTRP-6 were evaluated with enzyme-linked immunosorbent assay in 70 subjects (35 newly diagnosed Hashimoto's thyroiditis and 35 healthy subjects). Their relationship with the thyroid hormone and some biochemical factors was analyzed.
Results: The levels of CTRP3 and CTRP6 in patients with Hashimoto's disease were higher than those in the control group (p<0.05). There was a significant positive correlation between CTRP3 and TSH levels (r=0.286 and p=0.017). There was a significant relationship between CTRP3 and Fasting Blood Sugar (r=0.249 and p=0.038). There was a significant inverse negative correlation between CTRP6 levels and T3 (r=-0.269 and p=0.024), and T4 (r=-0.272 and p=0.023). Moreover, there was a significant positive correlation between CTRP6 serum levels and TSH serum levels (r=0.397 and p=0.001). There was a significant positive correlation between CTRP6 levels and Cholesterol (r=0.351 and p=0.003), and LDL (r=-0.244 and p=0.042).
Conclusions: Finally, our results demonstrated that serum levels of CTRP3 and CTRP6 are higher in patients with Hashimoto's compared to the control group and probably play a role in the pathogenesis of Hashimoto's thyroiditis.
{"title":"Evaluation of the serum level of CTRP-3 and CTRP-6 in patients with Hashimoto's disease and correlation with thyroid hormones and lipid profile.","authors":"Rafal Sameer Al-Abboody, Nadia Heydari, Mohsen Saravani, Shahin Nosaratzehi, Hamideh Akbari, Seyyed Mehdi Jafari","doi":"10.1515/jbcpp-2024-0060","DOIUrl":"10.1515/jbcpp-2024-0060","url":null,"abstract":"<p><strong>Objectives: </strong>Numerous studies show that the adipokines play a role in on the thyroid axis. The aim of this study was the evaluation of serum level of CTRP-3 and CTRP-6 as a member of the adipokines family in patients with Hashimoto's.</p><p><strong>Methods: </strong>The levels of CTRP-3 and CTRP-6 were evaluated with enzyme-linked immunosorbent assay in 70 subjects (35 newly diagnosed Hashimoto's thyroiditis and 35 healthy subjects). Their relationship with the thyroid hormone and some biochemical factors was analyzed.</p><p><strong>Results: </strong>The levels of CTRP3 and CTRP6 in patients with Hashimoto's disease were higher than those in the control group (p<0.05). There was a significant positive correlation between CTRP3 and TSH levels (r=0.286 and p=0.017). There was a significant relationship between CTRP3 and Fasting Blood Sugar (r=0.249 and p=0.038). There was a significant inverse negative correlation between CTRP6 levels and T3 (r=-0.269 and p=0.024), and T4 (r=-0.272 and p=0.023). Moreover, there was a significant positive correlation between CTRP6 serum levels and TSH serum levels (r=0.397 and p=0.001). There was a significant positive correlation between CTRP6 levels and Cholesterol (r=0.351 and p=0.003), and LDL (r=-0.244 and p=0.042).</p><p><strong>Conclusions: </strong>Finally, our results demonstrated that serum levels of CTRP3 and CTRP6 are higher in patients with Hashimoto's compared to the control group and probably play a role in the pathogenesis of Hashimoto's thyroiditis.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"61-67"},"PeriodicalIF":0.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder marked by repeated episodes of partial or complete upper airway obstruction during sleep, which leads to intermittent hypoxia and fragmented sleep. These disruptions negatively impact cardiovascular health, metabolic function, and overall quality of life. Obesity is a major modifiable risk factor for OSA, as it contributes to both anatomical and physiological mechanisms that increase the likelihood of airway collapse during sleep. While continuous positive airway pressure (CPAP) therapy remains the gold standard for OSA treatment, its limitations - particularly issues with patient adherence - underscore the need for alternative or adjunct therapeutic options. One such option is the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely recognized for their ability to reduce body weight and improve metabolic health. Emerging evidence suggests that GLP-1 RAs may offer therapeutic benefits in managing OSA, particularly by addressing obesity, a key contributor to the condition. This narrative review seeks to explore the role of GLP-1 RAs in the treatment of OSA, evaluating their efficacy in reducing OSA severity and discussing their broader clinical implications for future research and practice.
{"title":"Exploring the therapeutic potential of GLP-1 receptor agonists in the management of obstructive sleep apnea: a comprehensive review.","authors":"Amruth Akhil Alluri, Merin Mohan Kurien, Nikhil Patel Pokar, Alekhya Madarapu, Sreeja Sadam, Nikhitha Puvvala, Rajmohan Seetharaman","doi":"10.1515/jbcpp-2024-0193","DOIUrl":"10.1515/jbcpp-2024-0193","url":null,"abstract":"<p><p>Obstructive Sleep Apnea (OSA) is a prevalent sleep disorder marked by repeated episodes of partial or complete upper airway obstruction during sleep, which leads to intermittent hypoxia and fragmented sleep. These disruptions negatively impact cardiovascular health, metabolic function, and overall quality of life. Obesity is a major modifiable risk factor for OSA, as it contributes to both anatomical and physiological mechanisms that increase the likelihood of airway collapse during sleep. While continuous positive airway pressure (CPAP) therapy remains the gold standard for OSA treatment, its limitations - particularly issues with patient adherence - underscore the need for alternative or adjunct therapeutic options. One such option is the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely recognized for their ability to reduce body weight and improve metabolic health. Emerging evidence suggests that GLP-1 RAs may offer therapeutic benefits in managing OSA, particularly by addressing obesity, a key contributor to the condition. This narrative review seeks to explore the role of GLP-1 RAs in the treatment of OSA, evaluating their efficacy in reducing OSA severity and discussing their broader clinical implications for future research and practice.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"13-25"},"PeriodicalIF":0.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-09eCollection Date: 2025-01-01DOI: 10.1515/jbcpp-2024-0140
Hazem Ayesh, Azizullah Beran, Sajida Suhail, Suhail Ayesh, Kevin Niswender
Introduction: Metabolic-Associated Steatohepatitis-Related Liver Disease (MASLD) and, its progressive form, Metabolic-Associated Steatohepatitis (MASH) pose significant global health challenges. Current therapeutic strategies targeting metabolic abnormalities have shown promise but lack specificity for the liver. Thyroid hormones, particularly thyroid hormone receptor beta (THR-β) agonists like resmetirom, offer a targeted approach to liver-related pathways.
Content: A network meta-analysis (NMA) comparing different doses of resmetirom to placebo for MASLD and MASH was conducted. PubMed, Scopus, Cochrane, and Web of Science were searched for relevant randomized controlled trials (RCTs). Efficacy outcomes included histological, radiological, and biochemical parameters, while safety outcomes comprised adverse events and treatment discontinuation.
Summary: Resmetirom demonstrated dose-dependent efficacy in histological and radiological assessments, with the 100 mg dose showing superior MASH resolution and hepatic fat reduction. Biochemical markers indicated improved liver function with resmetirom treatment. However, adverse events, particularly diarrhea and nausea, were more prevalent in the resmetirom group, leading to higher treatment discontinuation rates.
Outlook: Resmetirom shows promise as a therapeutic option for MASLD and MASH management, with significant improvements in liver health parameters. However, safety concerns warrant careful monitoring in clinical practice. Further research is needed to optimize its long-term safety and efficacy.
代谢性脂肪性肝炎相关肝病(MASLD)及其进展形式代谢性脂肪性肝炎(MASH)构成了重大的全球健康挑战。目前针对代谢异常的治疗策略已经显示出希望,但对肝脏缺乏特异性。甲状腺激素,特别是甲状腺激素受体β (THR-β)激动剂,如雷司替龙,提供了肝脏相关途径的靶向途径。内容:进行了一项网络荟萃分析(NMA),比较了不同剂量的雷美替米与安慰剂治疗MASLD和MASH。检索PubMed、Scopus、Cochrane和Web of Science相关的随机对照试验(RCTs)。疗效结果包括组织学、放射学和生化参数,而安全性结果包括不良事件和停止治疗。总结:瑞司替龙在组织学和放射学评估中显示出剂量依赖性疗效,100 mg剂量显示出优越的MASH溶解和肝脏脂肪减少。生化指标显示雷司美康治疗后肝功能有所改善。然而,不良事件,特别是腹泻和恶心,在雷司替罗组更普遍,导致更高的治疗停药率。展望:瑞斯替龙有望作为MASLD和MASH管理的治疗选择,在肝脏健康参数方面有显著改善。然而,在临床实践中,安全问题需要仔细监测。需要进一步研究以优化其长期安全性和有效性。
{"title":"Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials.","authors":"Hazem Ayesh, Azizullah Beran, Sajida Suhail, Suhail Ayesh, Kevin Niswender","doi":"10.1515/jbcpp-2024-0140","DOIUrl":"10.1515/jbcpp-2024-0140","url":null,"abstract":"<p><strong>Introduction: </strong>Metabolic-Associated Steatohepatitis-Related Liver Disease (MASLD) and, its progressive form, Metabolic-Associated Steatohepatitis (MASH) pose significant global health challenges. Current therapeutic strategies targeting metabolic abnormalities have shown promise but lack specificity for the liver. Thyroid hormones, particularly thyroid hormone receptor beta (THR-β) agonists like resmetirom, offer a targeted approach to liver-related pathways.</p><p><strong>Content: </strong>A network meta-analysis (NMA) comparing different doses of resmetirom to placebo for MASLD and MASH was conducted. PubMed, Scopus, Cochrane, and Web of Science were searched for relevant randomized controlled trials (RCTs). Efficacy outcomes included histological, radiological, and biochemical parameters, while safety outcomes comprised adverse events and treatment discontinuation.</p><p><strong>Summary: </strong>Resmetirom demonstrated dose-dependent efficacy in histological and radiological assessments, with the 100 mg dose showing superior MASH resolution and hepatic fat reduction. Biochemical markers indicated improved liver function with resmetirom treatment. However, adverse events, particularly diarrhea and nausea, were more prevalent in the resmetirom group, leading to higher treatment discontinuation rates.</p><p><strong>Outlook: </strong>Resmetirom shows promise as a therapeutic option for MASLD and MASH management, with significant improvements in liver health parameters. However, safety concerns warrant careful monitoring in clinical practice. Further research is needed to optimize its long-term safety and efficacy.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"3-11"},"PeriodicalIF":0.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Acute myocardial infarction is a critical medical condition that poses a significant risk to life. It is distinguished by the abrupt cessation of blood flow to a specific segment of the cardiac muscle. Acute myocardial infarction accounts for more than 15 % of global mortality annually.
Methods and results: A total of 433 young patients admitted with acute coronary syndrome - myocardial infarction underwent thrombolysis with fibrin specific agents followed by underwent diagnostic coronary angiogram between 01.09.2021 and 31.10.2022. The odds ratio showed a value of 1.973, which is much higher than the individuals with diabetes (0.306). Young individuals (25.9 %) with hypertension have a greater chance of recovery by thrombolysis.
Conclusions: The factors that contribute for the myocardial infarction should be recognized and addressed. Recognizing and addressing these risk factors through education, lifestyle modifications, and early intervention are crucial for preventing myocardial infarction and promoting good health.
{"title":"Risk factor assessment for post-thrombolytic coronary angiogram normalcy in young myocardial infarction patients.","authors":"Venkatramani Mahadevan, Abirami Karuppiah, Shravan Venkatraman","doi":"10.1515/jbcpp-2024-0064","DOIUrl":"https://doi.org/10.1515/jbcpp-2024-0064","url":null,"abstract":"<p><strong>Objectives: </strong>Acute myocardial infarction is a critical medical condition that poses a significant risk to life. It is distinguished by the abrupt cessation of blood flow to a specific segment of the cardiac muscle. Acute myocardial infarction accounts for more than 15 % of global mortality annually.</p><p><strong>Methods and results: </strong>A total of 433 young patients admitted with acute coronary syndrome - myocardial infarction underwent thrombolysis with fibrin specific agents followed by underwent diagnostic coronary angiogram between 01.09.2021 and 31.10.2022. The odds ratio showed a value of 1.973, which is much higher than the individuals with diabetes (0.306). Young individuals (25.9 %) with hypertension have a greater chance of recovery by thrombolysis.</p><p><strong>Conclusions: </strong>The factors that contribute for the myocardial infarction should be recognized and addressed. Recognizing and addressing these risk factors through education, lifestyle modifications, and early intervention are crucial for preventing myocardial infarction and promoting good health.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"36 1","pages":"51-59"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Quality by design: how poor adherence to guidelines holds back urological app innovation.","authors":"Emanuele Capasso, Mariagrazia Marisei, Ferdinando Fusco, Enrico Sicignano, Felice Crocetto","doi":"10.1515/jbcpp-2024-0205","DOIUrl":"10.1515/jbcpp-2024-0205","url":null,"abstract":"","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: The pervasiveness of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide, with physical inactivity being one of the major risk factors. Hand grip strength (HGS) is an important indicator of overall physical functioning and has been associated with various health-related outcomes. The purpose of this study was to investigate the impact of physical activity on the HGS of patients with type 2 diabetes mellitus (T2DM). Furthermore, it scrutinizes the relationship between physical activity and HGS in terms of sex.
Methods: A cross-sectional study including a total of 140 patients with T2DM was performed. Physical activity levels were assessed via the International Physical Activity Questionnaire (IPAQ). HGS was measured via a Camry digital handgrip dynamometer. Statistical analysis was performed via SPSS software, and statistical approaches such as ANOVA, Pearson correlation and t tests were used.
Results: The results of this research will contribute to the detection of the influence of physical activity and its association with HGS. These findings reveal that physical activity has a significant effect on HGS and that there is a positive correlation between physical activity and increased hand grip strength in individuals with T2DM.
Conclusions: The outcomes offer valuable insights into physical activity and muscle strength, which can aid in the early detection of physical disability. The findings of this study will be valuable for healthcare providers and professionals to suggest relevant physical activities for diabetic patients.
{"title":"A cross-sectional study on the effects of physical activity on hand grip strength in type 2 diabetes mellitus patients.","authors":"Praveena Meyyazhagan, Thamaraiselvi Kanagaraj, Nachal Annamalai","doi":"10.1515/jbcpp-2024-0176","DOIUrl":"10.1515/jbcpp-2024-0176","url":null,"abstract":"<p><strong>Objectives: </strong>The pervasiveness of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide, with physical inactivity being one of the major risk factors. Hand grip strength (HGS) is an important indicator of overall physical functioning and has been associated with various health-related outcomes. The purpose of this study was to investigate the impact of physical activity on the HGS of patients with type 2 diabetes mellitus (T2DM). Furthermore, it scrutinizes the relationship between physical activity and HGS in terms of sex.</p><p><strong>Methods: </strong>A cross-sectional study including a total of 140 patients with T2DM was performed. Physical activity levels were assessed via the International Physical Activity Questionnaire (IPAQ). HGS was measured via a Camry digital handgrip dynamometer. Statistical analysis was performed via SPSS software, and statistical approaches such as ANOVA, Pearson correlation and t tests were used.</p><p><strong>Results: </strong>The results of this research will contribute to the detection of the influence of physical activity and its association with HGS. These findings reveal that physical activity has a significant effect on HGS and that there is a positive correlation between physical activity and increased hand grip strength in individuals with T2DM.</p><p><strong>Conclusions: </strong>The outcomes offer valuable insights into physical activity and muscle strength, which can aid in the early detection of physical disability. The findings of this study will be valuable for healthcare providers and professionals to suggest relevant physical activities for diabetic patients.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"27-37"},"PeriodicalIF":0.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142729014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-18eCollection Date: 2024-11-01DOI: 10.1515/jbcpp-2024-0122
Leila Elyasi, Mehrdad Jahanshahi, S B Jameie, Hatef Ghasemi Hamid Abadi, Emsehgol Nikmahzar, Masoumeh Khalili, Melika Jameie, Mana Jameie
{"title":"Corrigendum to: 6-OHDA mediated neurotoxicity in SH-SY5Y cellular model of Parkinson disease suppressed by pretreatment with hesperidin through activating L-type calcium channels.","authors":"Leila Elyasi, Mehrdad Jahanshahi, S B Jameie, Hatef Ghasemi Hamid Abadi, Emsehgol Nikmahzar, Masoumeh Khalili, Melika Jameie, Mana Jameie","doi":"10.1515/jbcpp-2024-0122","DOIUrl":"10.1515/jbcpp-2024-0122","url":null,"abstract":"","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"377"},"PeriodicalIF":0.0,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Several studies demonstrated the benefits of omega-3 fatty acids supplementation in chronic kidney disease (CKD) patients. The objective of this study was to investigate the effect of omega-3 fatty acids supplementation in body composition, specifically on the lean body mass and fat mass in hemodialysis patients.
Methods: In this randomized, double-blind, placebo-controlled clinical trial, a total of 120 end-stage renal disease (ESRD) patients were randomly allocated into two groups. The intervention group has taken three grams of omega-3 fatty acids daily while the placebo group received three grams of medium chain triglycerides (MCT) as a placebo for a total of 2 months. The changes in the body mass index (BMI) and body composition (fat mass, muscle, and visceral fat) were assessed at baseline and following the intervention.
Results: No significant difference was found in the mean of BMI, FAT, muscle, and visceral fat in the intervention group compared to the control group after the intervention. After two months of omega-3 fatty acid supplementation, the study found no statistically significant impact of omega-3 fatty acids supplementation on various indices of body composition. The effect of ω-3 supplementation in reducing visceral fat was close to significant (p=0.08).
Conclusions: This study suggests that there is currently inadequate evidence to support the effect of omega-3 fatty acid supplementation in improving anthropometric measurements in patients with CKD, except a partial effect on visceral fat. Further large-scale and long-term clinical trials are needed to confirm the present results.
{"title":"Effect of omega-3 fatty acids supplementation on muscle mass, fat mass, and visceral fat of hemodialysis patients; A randomized clinical trial.","authors":"Saheb Abbas Torki, Zahra Roumi, Atefeh Tahavorgar, Zahra Salimi, Saeideh Mohammadi, Soheila Shekari, Zahra Saeedirad, Arezoo Amjadi, Pouya Mirzaee, Hanieh Shafaei, Bojlul Bahar, Fatemeh Mofidi, Masoud Khosravi, Saeid Doaei, Maryam Gholamalizadeh","doi":"10.1515/jbcpp-2024-0148","DOIUrl":"10.1515/jbcpp-2024-0148","url":null,"abstract":"<p><strong>Objectives: </strong>Several studies demonstrated the benefits of omega-3 fatty acids supplementation in chronic kidney disease (CKD) patients. The objective of this study was to investigate the effect of omega-3 fatty acids supplementation in body composition, specifically on the lean body mass and fat mass in hemodialysis patients.</p><p><strong>Methods: </strong>In this randomized, double-blind, placebo-controlled clinical trial, a total of 120 end-stage renal disease (ESRD) patients were randomly allocated into two groups. The intervention group has taken three grams of omega-3 fatty acids daily while the placebo group received three grams of medium chain triglycerides (MCT) as a placebo for a total of 2 months. The changes in the body mass index (BMI) and body composition (fat mass, muscle, and visceral fat) were assessed at baseline and following the intervention.</p><p><strong>Results: </strong>No significant difference was found in the mean of BMI, FAT, muscle, and visceral fat in the intervention group compared to the control group after the intervention. After two months of omega-3 fatty acid supplementation, the study found no statistically significant impact of omega-3 fatty acids supplementation on various indices of body composition. The effect of ω-3 supplementation in reducing visceral fat was close to significant (p=0.08).</p><p><strong>Conclusions: </strong>This study suggests that there is currently inadequate evidence to support the effect of omega-3 fatty acid supplementation in improving anthropometric measurements in patients with CKD, except a partial effect on visceral fat. Further large-scale and long-term clinical trials are needed to confirm the present results.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"347-352"},"PeriodicalIF":0.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Hypertension affects approximately 1.28 billion adults worldwide, driving the search for integrative therapeutic approaches alongside conventional treatments. While chromotherapy, particularly blue light exposure, has historical roots in traditional medicine and its specific impact on blood pressure regulation remains understudied. So, the present study aims to investigate the immediate impact of exposure to blue glass through sunlight on blood pressure in hypertensive individuals.
Methods: This randomized controlled trial was carried out with a sample of 60 hypertensive patients, who were divided into two groups: a study group that received blue glass exposure for 20 min and a control group that received exposure to colourless glass. The primary outcome measures were systolic and diastolic blood pressure, pulse rate, and oxygen saturation levels.
Results: The results of the study revealed statistically significant differences in systolic blood pressure (p=0.006) and pulse rate (p=0.005) after the intervention in the study group and no such changes were noted in the control group.
Conclusions: The findings of this study suggest that blue glass exposure has a significant impact on reducing blood pressure and pulse rate in hypertensive patients, indicating its potential use as a integrative treatment in the management of hypertension.
{"title":"Immediate effect of sunlight exposure through blue glass on blood pressure in hypertensive patients: a randomized controlled trial.","authors":"Deepa Yoganathan, Maheshkumar Kuppusamy, Edmin Christa, Saran Murugan, Vijayabharathi Elangovan, Preetha Jayakumar, Sangamithraa Rammohan","doi":"10.1515/jbcpp-2024-0081","DOIUrl":"10.1515/jbcpp-2024-0081","url":null,"abstract":"<p><strong>Objective: </strong>Hypertension affects approximately 1.28 billion adults worldwide, driving the search for integrative therapeutic approaches alongside conventional treatments. While chromotherapy, particularly blue light exposure, has historical roots in traditional medicine and its specific impact on blood pressure regulation remains understudied<b>.</b> So, the present study aims to investigate the immediate impact of exposure to blue glass through sunlight on blood pressure in hypertensive individuals.</p><p><strong>Methods: </strong>This randomized controlled trial was carried out with a sample of 60 hypertensive patients, who were divided into two groups: a study group that received blue glass exposure for 20 min and a control group that received exposure to colourless glass. The primary outcome measures were systolic and diastolic blood pressure, pulse rate, and oxygen saturation levels.</p><p><strong>Results: </strong>The results of the study revealed statistically significant differences in systolic blood pressure (p=0.006) and pulse rate (p=0.005) after the intervention in the study group and no such changes were noted in the control group.</p><p><strong>Conclusions: </strong>The findings of this study suggest that blue glass exposure has a significant impact on reducing blood pressure and pulse rate in hypertensive patients, indicating its potential use as a integrative treatment in the management of hypertension.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":"371-374"},"PeriodicalIF":0.0,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}